Genzyme Biosurgery cuts for profitability in 18 months
This article was originally published in Clinica
Genzyme Biosurgery is to restructure its operations in a bid to reach operating profitability within one and a half years. The move will see the company streamline operations (including the closure of a factory), restrict R&D funding and slash up to 235 jobs in order to reduce operating costs. The company also plans to sell its Snowden-Pencer surgical instruments line.